The overuse of broad-spectrum antibiotics has led to the marked rise of multidrug-resistant bacteria, putting us on the verge of a post-antibiotic era in which common infections can be serious or life-threatening. Broad-spectrum antibiotics are also recognized to disrupt the ecology of the human microbiome leading to disease. C3J Therapeutics is focused on improving human health through the development of novel targeted antimicrobials utilizing two proprietary platforms – synthetic bacteriophage and antimicrobial peptides.
